Upstate Active Clinical Trials

Study Title:

64407564MMY3002 (MonumenTAL-3) - A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy

What is the purpose of the study? (in Layman's terms, please describe the study)

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).

Upstate Institutional Review Board (IRB) Number:

2057886

Study/Protocol ID:

64407564MMY3002 (MonumenTAL-3)

Study Phase:

Patient Age Group:

Adults

Principal Investigator:

Krishna B Ghimire, MD

What is involved if I participate?

How long is the study?
10 years
Is transportation provided or reimbursed?
Yes
Is parking provided or reimbursed?
Yes
What tests and procedures are involved?
Blood draws, ECGs, MRI/CT/X-ray, bone marrow biopsy/aspirate,

Where will the study take place?

SUNY Upstate Medical University

Other Information:

N/A

ClinicalTrials.Gov ID:

NCT05455320

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: AMY BUBB
Phone: 315-464-5788
Email: [email protected]

Return to Previous Page || Search Again